10590445 - GAU: 1614 Receipt date: 03/18/2010

PTO/SB/08A/B (09-06)
Approved for use through 03/31/2007. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO				Complete if Known		
				Application Number	10/590,445 – Conf. # 6734	
l IN	<b>NFORMATION</b>	1 DI	SCLOSURE	Filing Date	August 24, 2006	
l s	TATEMENT E	3Y /	APPLICANT	First Named Inventor	Michael Jung	
				Art Unit	1614	
	(Use as many she	eets as	s necessary)	Examiner Name	James D. Anderson	
Sheet	3	of	7	Attorney Docket Number	58086-235854	

		C10	Keewn et al. Methods in Enzymology. 185:527.527.(1990).		000000000000
***************************************	************	-C4+	Mansour et al., Nature, 938,946-952 (1986).	********	
000000000000000000000000000000000000000			Muller et al., 1991, Moi. & Cell. Blo. 11.1785.	2000000000	0000000000000
000000000000000000000000000000000000000		<del></del>	· · ·	000000000	000000000000000000000000000000000000000
		C14	Unaub et al., <u>Froc. Nati. Acad. Sci. USA, 77</u> .4216 (1980). Stinehoemb et al., Nature, 282:30 (1970).		
		<del>∞⊚4•5</del> ∞∞		,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,	
			Kingsman et al., <u>Gene, 7</u> . 141 (1979).		
	10 D /		Tschumper et al., <u>Genie, 10</u> . 137 (1980).		
	/S.R./	C17	Jones, <u>Genetics</u> , <u>85</u> :23 (1977).		
	000000000000000000000000000000000000000	h4660g0600000	Feldman, B.d. & Feldman, D. The development of androgen independent prostate	000000000	00000000000000
		₩₩₩₩₩₩₩₩₩	cancer. Nat Rev Cancer 1, 34-45 (2001).		
000000000000000000000000000000000000000	000000000000000000000000000000000000000	hq60gdqbbacco	Gelmann, E.P. Melecular biology of the androgen receptor. J Glin Oncol 20, 0001-15	000000000	00000000000000
		C20	(2002).		
	000000000000000000000000000000000000000	40000000000000000000000000000000000000	Dally, G.P. Andregen receptor as a target in andregen independent prostate cancer:	0000000000	000000000000000000000000000000000000000
000000000000000000000000000000000000000		000000000000000000000000000000000000000	Urology 60, 132-8; discussion 138-9 (2002).		
		<del>1021</del>	Taplin, IVI.E. et al. Selection for androgen receptor mutations in prostate cancers		
		-000	treated with androgen antagonist. Cancer Res 59, 2511-5 (1999).		
***************************************		<del></del>	Taplin, M.E. et al. Androgen receptor mutations in androgen-independent prostate		
		C23	cancer: Cancer and Leukemia Group B Study 9663. J Clin Oncol 21, 2673-8 (2003).		
		<del>himaninana</del>	Visakerpi, Tot al. In vive amplification of the andregen receptor gene and progression of human prostate cancer. Nat Genet 9, 401-6 (1995).	************	*************
		C24	Taplin; M.E. et al: Mutation of the androgen receptor gene in metastatic androgen		
***************************************	000000000000000000000000000000000000000	00000000000000000000000000000000000000	independent prostate cancer. N Engl J Med 332, 1393-8 (1995).	000000000	900000000000000000000000000000000000000
200000000000000000000000000000000000000	***************************************	000000000000000000000000000000000000000		000000000	000000000000000000000000000000000000000
000000000000000000000000000000000000000	000000000000000000000000000000000000000	<del></del>	Veidscholte, J. et al. A mutation in the ligand binding domain of the androgen	000000000	000000000000000000000000000000000000000
300000000000000000000000000000000000000		<del></del>	Veidscholte, J. et al. A mutation in the ligand binding domain of the androgen receptor of human LNCaP cells affects steroid binding characteristics and response	000000000	000000000000000000000000000000000000000
000000000000000000000000000000000000000	000000000000000000000000000000000000000		Veidscholte, J. et al. A mutation in the ligand binding domain of the androgen receptor of human LNCaP cells affects steroid binding characteristics and response to anti-androgens. Biochem Biophys Res Commun 173, 534-40 (1990).	200000000	000000000000000000000000000000000000000
000000000000000000000000000000000000000		~ <del>@@</del> &~~~	Veldscholte, J. et al. A mutation in the figand binding domain of the androgen receptor of human LNCaP cells affects steroid binding characteristics and response to anti-androgens. Biochem Biophys Res Commun 173, 534-40 (1990).  Matias, P.M. et al. Structural basis for the glucocorticoid response in a mutant human	200000000	000000000000000000000000000000000000000
00000000000000000000000000000000000000			Veldscholte, J. et al. A mutation in the figand binding domain of the androgen receptor of human LNCaP cells affects steroid binding characteristics and response to anti-androgens. Biochem Biophys Res Commun 173, 534-40 (1990).  Matias, P.M. et al. Structural basis for the glucocorticoid response in a mutant human androgen receptor (AR(ccr)) derived from an androgen-independent prostate cancer.	2000000000	000000000000000000000000000000000000000
			veldscholte, J. et al. A mutation in the figand binding domain of the androgen receptor of human LNCaP cells affects steroid binding characteristics and response to anti-androgens. Biochem Biophys Res Commun 173, 534-40 (1990).  Matias, P.M. et al. Otrustural basis for the glucocorticoid response in a mutant human androgen receptor (AR(ccr)) derived from an androgen-independent prostate cancer. J Med Chem 45, 1439-46 (2002).	2000000000	000000000000000000000000000000000000000
	000000000000000000000000000000000000000	~ <del>@@</del>	veldscholte, J. et al. A mutation in the figand binding domain of the androgen receptor of human LNCaP cells affects steroid binding characteristics and response to anti-androgens. Biochem Biophys Res Commun 173, 534-40 (1990).  Matias, P.M. et al. Structural basis for the glucocorticoid response in a mutant human androgen receptor (AR(ccr)) derived from an androgen-independent prostate cancer. J Med Chem 45, 1439-46 (2002).  Craft, N., Shostak, Y., Carey, M. & Sawyers, C.L. A mechanism for hormone-	200000000	000000000000000000000000000000000000000
000000000000000000000000000000000000000		~ <del>@@</del>	veldscholte, J. et al. A mutation in the figand binding domain of the androgen receptor of human LNCaP cells affects steroid binding characteristics and response to anti-androgens. Biochem Biophys Res Commun 173, 534-40 (1990).  Matias, P.M. et al. Otrustural basis for the glucocorticoid response in a mutant human androgen receptor (AR(ccr)) derived from an androgen-independent prostate cancer. J Med Chem 45, 1439-46 (2002).	2000000000	000000000000000000000000000000000000000
		~ <del>@@</del>	Veldscholte, J. et al. A mutation in the ligand binding domain of the androgen receptor of human LNCaP cells affects steroid binding characteristics and response to anti-androgens. Biochem Biophys Res Commun 173, 534-40 (1990).  Matias, P.M. et al. Structural basis for the glucocorticoid esponse in a mutant human androgen receptor (AR(ccr)) derived from an androgen-independent prostate cancer. J Med Chem 45, 1439-46 (2002).  Craft, N., Shostak, Y., Carey, M. & Sawyers, C.L. A mechanism for hormone-independent prostate cancer through modulation of androgen receptor signaling by the HER-2/neu tyrosine kinase. Nat Med 5, 280-5 (1999).	300000000	000000000000000000000000000000000000000
	00000000000000000000000000000000000000	00000000000000000000000000000000000000	Veldscholte, J. et al. A mutation in the ligand binding domain of the androgen receptor of human LNCaP cells affects steroid binding characteristics and response to anti-androgens. Biochem Biophys Res Commun 173, 534-40 (1990).  Matias, P.M. et al. Structural basis for the glucocorticoid response in a mutant human androgen receptor (AR(ccr)) derived from an androgen-independent prostate cancer. J Med Chem 45, 1439-46 (2002).  Craft, N., Shostak, Y., Carey, M. & Sawyers, C.L. A mechanism for hormone-independent prostate cancer through modulation of androgen receptor signaling by the HER-2/neu tyrosine kinase. Nat Med 5, 280-5 (1999).  Ciscli: D. et al. Androgen receptor phosphorylation. Regulation and identification of	200000000	
		00000000000000000000000000000000000000	Veldscholte, J. et al. A mutation in the ligand binding domain of the androgen receptor of human LNCaP cells affects steroid binding characteristics and response to anti-androgens. Biochem Biophys Res Commun 173, 534-40 (1990).  Matias, P.M. et al. Structural basis for the glucocorticoid response in a mutant human androgen receptor (AR(ccr)) derived from an androgen-independent prostate cancer. J Med Chem 45, 1439-46 (2002).  Craft, N., Shostak, Y., Carey, M. & Sawyers, C.L. A mechanism for hormone-independent prostate cancer through modulation of androgen receptor signaling by the HER-2/neu tyrosine kinase. Nat Med 5, 280-5 (1999).  Giseli, B. et al. Androgen receptor pheophorylation. Regulation and identification of the phosphorylation sites. J Biol Chem 277, 29304-14 (2002).	2000000000	000000000000000000000000000000000000000
		00000000000000000000000000000000000000	Veldscholte, J. et al. A mutation in the ligand binding domain of the androgen receptor of human LNCaP cells affects steroid binding characteristics and response to anti-androgens. Biochem Biophys Res Commun 173, 534-40 (1990).  Matias, P.M. et al. Structural basis for the glucocorticoid response in a mutant human androgen receptor (AR(ccr)) derived from an androgen-independent prostate cancer. J Med Chem 45, 1439-46 (2002).  Craft, N., Shostak, Y., Carey, M. & Sawyers, C.L. A mechanism for hormone-independent prostate cancer through modulation of androgen receptor signaling by the HER-2/neu tyrosine kinase. Nat Med 5, 280-5 (1999).  Ciscli: D. et al. Androgen receptor phosphorylation. Regulation and identification of	2000000000 2000000000	00000000000000000000000000000000000000
		00000000000000000000000000000000000000	Verdscholte, J. et al. A mutation in the ligand binding domain of the androgen receptor of human LNCaP cells affects steroid binding characteristics and response to anti-androgens. Biochem Biophys Res Commun 173, 534-40 (1990).  Matias, P.M. et al. Structural basis for the glucocorticoid response in a mutant human androgen receptor (AR(ccr)) derived from an androgen-independent prostate cancer. J Med Chem 45, 1439-46 (2002).  Craft, N., Shostak, T., Carey, M. & Sawyers, C.L. A mechanism for homone-independent prostate cancer through modulation of androgen receptor signaling by the HER-2/neu tyrosine kinase. Nat Med 5, 280-5 (1999).  Ciscli, B. et al. Androgen receptor pheopherylation. Pogulation and identification of the phosphorylation sites. J Biol Chem 277, 29304-14 (2002).  Kato, S. et al. Activation of the estrogen receptor through phosphorylation by	20000000000000000000000000000000000000	
			Veldscholte, J. et al. A mutation in the ligand binding domain of the androgen receptor of human LNCaP cells affects steroid binding characteristics and response to anti-androgens. Biochem Biophys Res Commun 173, 534-40 (1990).  Matias, P.M. et al. Otrustural basis for the glucocorticoid response in a mutant human androgen receptor (AR(ccr)) derived from an androgen-independent prostate cancer. J Med Chem 45, 1439-46 (2002).  Craft, N., Shostak, Y., Carey, M. & Sawyers, C.L. A mechanism for hormone-independent prostate cancer through modulation of androgen receptor signaling by the HER-2/neu tyrosine kinase. Nat Med 5, 280-5 (1999).  Giseli, B. et al. Androgen receptor phosphorylation. Regulation and identification of the phosphorylation sites. J Biol Chem 277, 29304-14 (2002).  Kato, S. et al. Activation of the singen receptor through phosphorylation by mitogen-activated protein kinase. Science 270, 1491-4 (1995).  Font de Mora, d. & Brown, M. AlB1 is a conduit for kinase mediated growth factor signaling to the estrogen receptor. Mol Cell Biol 20, 5041-7 (2000).	30000000000000000000000000000000000000	
			Veldscholte, J. et al. A mutation in the ligand binding domain of the androgen receptor of human LNCaP cells affects steroid binding characteristics and response to anti-androgens. Biochem Biophys Res Commun 173, 534-40 (1990).  Matias, P.M. et al. Structural basis for the glucocorticoid response in a mutant human androgen receptor (AR(ccr)) derived from an androgen-independent prostate cancer. J Med Chem 45, 1439-46 (2002).  Craft, N., Shostak, Y., Carey, M. & Sawyers, C.L. A mechanism for hormone-independent prostate cancer through modulation of androgen receptor signaling by the HER-2/neu tyrosine kinase. Nat Med 5, 280-5 (1999).  Ciseli, B. et al. Androgen receptor phosphorylation. Regulation and identification of the phosphorylation sites. J Biol Chem 277, 29304-14 (2002).  Kato, S. et al. Activation of the estrogen receptor through phosphorylation by mitogen-activated protein kinase. Science 270, 1491-4 (1995).  Font de Mora, J. & Brown, M. AlD1 is a conduit for kinase mediated growth factor signaling to the estrogen receptor. Mol Cell Biol 20, 5041-7 (2000).  Trembley, A. Trembley, C.B. Labrie, E. & Giguere, V. Ligand independent		
	00000000000000000000000000000000000000		Veldscholte, J. et al. A mutation in the ligand binding domain of the androgen receptor of human LNCaP cells affects steroid binding characteristics and response to anti-androgens. Biochem Biophys Res Commun 173, 534-40 (1990).  Matias, P.M. et al. Structural basis for the glucocorticoid response in a mutant human androgen receptor (AR(ccr)) derived from an androgen-independent prostate cancer. J Med Chem 45, 1439-46 (2002).  Craft, N., Shostak, r., Carey, M. & Sawyers, C.L. A mechanism for hormone-independent prostate cancer through modulation of androgen receptor signaling by the HER-2/neu tyrosine kinase. Nat Med 5, 280-5 (1999).  Ciseli, D. et al. Androgen receptor phespherylation. Regulation and identification of the phosphorylation sites. J Biol Chem 277, 29304-14 (2002).  Kato, S. et al. Activation of the estrogen receptor through phosphorylation by mitogen-activated protein kinase. Science 270, 1491-4 (1995).  Font de Mora, J. & Brown, M. AID1 is a conduit for kinase-mediated growth factor signaling to the estrogen receptor. Mol Cell Biol 20, 5041-7 (2000).  Trombley, A. Trombley, C.B. Labrio, E. & Giguero, V. Ligand independent recruitment of SRC-1 to estrogen receptor beta through phosphorylation of activation	00000000000000000000000000000000000000	
			Veldscholte, J. et al. A mutation in the ligand binding domain of the androgen receptor of human LNCaP cells affects steroid binding characteristics and response to anti-androgens. Biochem Biophys Res Commun 173, 534-40 (1990).  Matias, P.M. et al. Structural basis for the glucocorticoid response in a mutant human androgen receptor (AR(ccr)) derived from an androgen-independent prostate cancer. J Med Chem 45, 1439-46 (2002).  Craft, N., Shostak, Y., Carey, M. & Sawyers, C.L. A mechanism for hormone-independent prostate cancer through modulation of androgen receptor signaling by the HER-2/neu tyrosine kinase. Nat Med 5, 280-5 (1999).  Ciseli, B. et al. Androgen receptor phosphorylation. Regulation and identification of the phosphorylation sites. J Biol Chem 277, 29304-14 (2002).  Kato, S. et al. Activation of the estrogen receptor through phosphorylation by mitogen-activated protein kinase. Science 270, 1491-4 (1995).  Font de Mora, J. & Brown, M. AlD1 is a conduit for kinase mediated growth factor signaling to the estrogen receptor. Mol Cell Biol 20, 5041-7 (2000).  Trembley, A. Trembley, C.B. Labrie, E. & Giguere, V. Ligand independent	00000000000000000000000000000000000000	

Examiner Signature /Savitha Rao/	Date Considered	03/23/2010
----------------------------------	--------------------	------------